ALK opjusterer forventningerne til 2022
04 août 2022 07h37 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddeler i dag, at selskabet baseret på et stærkt salgsmomentum og forventningerne til resten af året har opjusteret forventningerne til hele året. Som følge...
ALK upgrades its full-year financial outlook
04 août 2022 07h37 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that based on a strong sales momentum and the outlook for the remainder of the year, ALK has upgraded its full-year outlook. As a result: ...
ALK spotlights the impact of respiratory allergies on children at EAACI Congress
03 juil. 2022 06h45 HE
|
ALK Abello
Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the EAACI CongressThe growing availability of evidence-based...
ALK påbegynder klinisk studie med tabletvaccine til behandling af peanutallergi
27 juin 2022 06h44 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK igangsætter et klinisk fase I-studie med sin nye, sublinguale tabletvaccine (SLIT-tablet) til behandling af peanutallergi. Studiet markerer den...
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
27 juin 2022 06h44 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy. The...
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
19 mai 2022 12h15 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
19 mai 2022 12h15 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
17 mai 2022 14h43 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
17 mai 2022 14h43 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
Three-month interim report (Q1) 2022
12 mai 2022 01h30 HE
|
ALK Abello
ALK reports Q1 revenue growth of 11% with tablet sales up 24% and earnings up 20% (unaudited) ALK delivered strong financial performance in Q1, with revenue up 11% and tablets as the primary driver...